Notably, ERBB2, also known as HER2, has been well-documented for its overexpression in breast cancer and is a validated therapeutic target [49,50], as is EGFR, which is implicated in various cancers including breast cancer [51,52]. Here, EGFR is linked to breast carcinoma.